BeiGene Competitors, Revenue, Alternatives and Pricing

Claim your profile


Boston, MA USA
Total Funding:$529.6M
Lead Investor(s):N/A

Estimated Revenue & Financials

  • BeiGene's estimated annual revenue is currently $213.4M per year.(?)
  • BeiGene received $800.0M in venture funding in January 2018.
  • BeiGene's estimated revenue per employee is $155,000
  • BeiGene's total funding is $529.6M.

Employee Data

  • BeiGene has 1377 Employees.(?)
  • BeiGene grew their employee count by 44% last year.
  • BeiGene currently has 1 job openings.

BeiGene, Ltd. (NASDAQ: BGNE) is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,300 employees in China, the United States (Cambridge, MA; Fort Lee, NJ; Emeryville, CA & San Mateo, CA), Switzerland and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for the treatment of cancer. BeiGene is working to create combination solutions aimed at having both a meaningful and lasting impact on cancer patients. For more information, see